GO:1990168 protein K33-linked deubiquitination: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990168 describes the removal of K33-linked polyubiquitin chains from substrate proteins by deubiquitinating enzymes (DUBs).
• K33-linked deubiquitination regulates key signaling proteins such as NLRP3, CARD9, CTSB, CDK1, TBK1, and HECTD1.
• DUBs including ZRANB1, YOD1, OTUD1, OTUD4, TRABID, and USP38 catalyze K33-linked deubiquitination.
• Dysregulation of K33-linked deubiquitination is linked to hepatocellular carcinoma, sepsis-induced DIC, inflammatory heart remodeling, glioblastoma, and autophagy-related diseases.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect the causal roles of K33-specific DUBs and substrates.
• EDITGENE provides end-to-end CRISPR cell model and screening services to accelerate functional studies of K33-linked deubiquitination.
Description
Protein K33-linked deubiquitination (GO:1990168) is a biological process in which a K33-linked ubiquitin chain, a polymer formed by linkages between lysine 33 of ubiquitin monomers, is removed from a target protein. This process is catalyzed by specialized deubiquitinating enzymes (DUBs) that cleave the isopeptide bond between ubiquitin K33 and the substrate, thereby reversing a specific ubiquitin signal. Unlike K48-linked chains that typically target proteins for proteasomal degradation, K33-linked chains often serve non-degradative roles in signaling, trafficking, and immune regulation, making their removal a critical regulatory step. Researchers study GO:1990168 to understand how cells fine-tune inflammatory responses, cell cycle progression, and stress adaptation. The clinical relevance of this process is underscored by its implication in hepatocellular carcinoma, sepsis-induced disseminated intravascular coagulation (DIC), inflammatory heart remodeling, and glioblastoma. As the list of K33-specific DUBs and substrates grows, precise CRISPR-based models are needed to establish causality and therapeutic potential.
protein K33-linked deubiquitination At A Glance
| GO ID | GO:1990168 |
|---|---|
| GO term | protein K33-linked deubiquitination |
| Ontology | biological_process |
| Synonym | None |
| Major function | Removal of K33-linked polyubiquitin chains from substrate proteins by deubiquitinating enzymes |
| Key enzymes | ZRANB1, YOD1, OTUD1, OTUD4, TRABID, USP38 |
| Key substrates | CTSB, NLRP3, CARD9, CDK1, HECTD1, TBK1 |
| Associated diseases | Hepatocellular carcinoma, sepsis-induced DIC, inflammatory heart remodeling, glioblastoma |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, ubiquitin chain-specific antibodies, mass spectrometry |
What Is GO:1990168?
According to the Gene Ontology, GO:1990168 (protein K33-linked deubiquitination) is a protein deubiquitination process in which a K33-linked ubiquitin chain, i.e. a polymer of ubiquitin formed by linkages between lysine residues at position 33 of the ubiquitin monomers, is removed from a protein. In simpler terms, it is the enzymatic erasure of a specific type of ubiquitin tag that is built through lysine 33 of ubiquitin. This process is distinct from deubiquitination of K48-, K63-, or K11-linked chains and is mediated by DUBs with specificity for K33 linkages.
Why Is protein K33-linked deubiquitination Important in Cell Biology?
GO:1990168 is important because K33-linked deubiquitination acts as a molecular switch that controls the stability, localization, and activity of key signaling proteins. For example, ZRANB1-mediated K33 deubiquitination of CTSB promotes ferroptosis in HBV-related hepatocellular carcinoma, while YOD1 protects against MRSA sepsis-induced DIC through K33-linked deubiquitination of NLRP3. OTUD1 deubiquitinates CARD9 to drive isoproterenol-induced inflammatory heart remodeling, and OTUD4 deubiquitinates CDK1 to activate MAPK signaling in glioblastoma. TRABID stabilizes the K29/K48-specific E3 ligase HECTD1 via K33 deubiquitination, and USP38 edits TBK1 ubiquitination to inhibit type I interferon signaling. These examples illustrate that K33-linked deubiquitination is a central node in inflammation, cancer, and cell death pathways, making it a high-value target for mechanistic and therapeutic research.
• Controls inflammatory signaling by regulating NLRP3 and CARD9 stability and activity.
• Modulates cancer progression through CTSB, CDK1, and HECTD1 in hepatocellular carcinoma and glioblastoma.
• Regulates type I interferon signaling via TBK1 editing by USP38.
• Influences autophagosome maturation through UVRAG ubiquitination and deubiquitination.
• Determines the fate of K33-linked substrates in ferroptosis and cell death pathways.
• Provides a reversible switch for non-degradative ubiquitin signaling.
• Offers potential therapeutic targets for sepsis, heart failure, and cancer.
• Requires precise CRISPR models to distinguish K33-specific effects from other ubiquitin linkages.
What Happens During protein K33-linked deubiquitination?
Recognition of K33-linked ubiquitin chains
In simple terms: The enzyme first finds and binds the specific K33-linked ubiquitin chain on the target protein.
DUBs such as ZRANB1, YOD1, OTUD1, OTUD4, TRABID, and USP38 contain ubiquitin-binding domains that recognize K33-linked chains. For example, ZRANB1 specifically interacts with K33-linked chains on CTSB to promote its deubiquitination. YOD1 recognizes K33-linked NLRP3 during MRSA sepsis. This recognition step ensures substrate specificity and prevents off-target cleavage of other ubiquitin linkages.
Catalytic cleavage of the K33 isopeptide bond
In simple terms: The enzyme cuts the bond between ubiquitin K33 and the substrate, removing the chain.
The catalytic domain of the DUB, often an OTU or USP domain, hydrolyzes the isopeptide bond between the C-terminus of ubiquitin and lysine 33 of the distal ubiquitin or the substrate. OTUD1 cleaves K33-linked chains from CARD9, while OTUD4 removes K33-linked ubiquitin from CDK1. TRABID stabilizes HECTD1 by cleaving K33-linked chains. This cleavage is highly specific and reversible.
Downstream signaling consequences
In simple terms: Removing the K33 chain changes what the target protein does, often turning a signal on or off.
Deubiquitination of CTSB by ZRANB1 promotes ferroptosis in HBV-related hepatocellular carcinoma. YOD1-mediated K33 deubiquitination of NLRP3 protects against MRSA sepsis-induced DIC. OTUD1-CARD9 axis drives isoproterenol-induced inflammatory heart remodeling. OTUD4 deubiquitinates CDK1 to activate MAPK signaling in glioblastoma. USP38 edits TBK1 ubiquitination to inhibit type I interferon signaling. These downstream effects link K33 deubiquitination to cell death, inflammation, and cancer.
Regulation of DUB activity and specificity
In simple terms: The enzymes themselves are controlled so that K33 deubiquitination happens at the right time and place.
DUB activity can be regulated by post-translational modifications, interacting partners, and substrate availability. For instance, the NLRP4 signalosome recruits USP38 to edit TBK1 ubiquitination. OTUD1 and OTUD4 are regulated in a context-dependent manner in heart and brain tissues. TRABID stability and activity influence HECTD1 levels. This layer of regulation ensures that K33 deubiquitination is tightly coupled to cellular signals.
Key Genes Involved in GO:1990168 protein K33-linked deubiquitination
The following genes and proteins are experimentally implicated in K33-linked deubiquitination or its regulation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ZRANB1 | DUB that removes K33-linked chains from CTSB | Promotes ferroptosis in HBV-related hepatocellular carcinoma |
| YOD1 | DUB that deubiquitinates NLRP3 via K33 linkages | Protects against MRSA sepsis-induced DIC |
| OTUD1 | DUB that deubiquitinates CARD9 | Drives isoproterenol-induced inflammatory heart remodeling |
| OTUD4 | DUB that deubiquitinates CDK1 | Promotes glioblastoma progression via MAPK signaling |
| TRABID | DUB that stabilizes HECTD1 via K33 deubiquitination | Regulates E3 ligase stability |
| USP38 | DUB that edits TBK1 ubiquitination | Inhibits type I interferon signaling |
| CTSB | Substrate of ZRANB1-mediated K33 deubiquitination | Ferroptosis in hepatocellular carcinoma |
| NLRP3 | Substrate of YOD1-mediated K33 deubiquitination | Sepsis-induced DIC |
| CARD9 | Substrate of OTUD1-mediated K33 deubiquitination | Inflammatory heart remodeling |
| CDK1 | Substrate of OTUD4-mediated K33 deubiquitination | Glioblastoma progression |
| HECTD1 | E3 ligase stabilized by TRABID | K29/K48 ubiquitin signaling |
| TBK1 | Substrate of USP38-mediated ubiquitin editing | Type I interferon signaling |
| UVRAG | Regulated by SMURF1-mediated ubiquitination | Autophagosome maturation and HCC growth |
| NLRP4 | Component of signalosome that recruits USP38 | TBK1 ubiquitination editing |
| SMURF1 | E3 ligase for UVRAG | Autophagy and hepatocellular carcinoma |
| Eimeria tenella OTU DUB | Interacts with viral RDRP | Parasite-virus interaction |
How Is protein K33-linked deubiquitination Regulated?
K33-linked deubiquitination is regulated at multiple levels. DUB recruitment to substrates can be mediated by scaffold proteins such as the NLRP4 signalosome, which brings USP38 to TBK1. Substrate availability and post-translational modifications of DUBs also influence activity. In heart tissue, OTUD1 expression and activity are induced by isoproterenol, linking adrenergic signaling to K33 deubiquitination of CARD9. In glioblastoma, OTUD4-mediated CDK1 deubiquitination activates MAPK signaling, suggesting crosstalk with kinase cascades. TRABID stability affects HECTD1 levels, indirectly influencing K29/K48 ubiquitination. These regulatory layers ensure context-specific outcomes.
protein K33-linked deubiquitination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ZRANB1 | HBV-related hepatocellular carcinoma, ferroptosis | CRISPR KO in HCC cell lines, xenograft models |
| YOD1 | MRSA sepsis-induced DIC | CRISPR KO in macrophages, sepsis mouse models |
| OTUD1 | Inflammatory heart remodeling | CRISPR KO in cardiomyocytes, isoproterenol mouse models |
| OTUD4 | Glioblastoma | CRISPR KO in glioblastoma cells, orthotopic xenografts |
| USP38 | Type I interferon signaling | CRISPR KO in immune cells, viral infection models |
K33-linked deubiquitination in hepatocellular carcinoma
ZRANB1 promotes ferroptosis in HBV-related hepatocellular carcinoma by regulating CTSB K33-linked deubiquitination. This suggests that K33 deubiquitination can either promote or suppress tumor growth depending on the substrate and context. UVRAG ubiquitination by SMURF1 also affects autophagosome maturation and inhibits hepatocellular carcinoma growth, highlighting the interplay between ubiquitination and deubiquitination in liver cancer.
K33-linked deubiquitination in sepsis and inflammation
YOD1 protects against MRSA sepsis-induced DIC through K33-linked deubiquitination of NLRP3. OTUD1-CARD9 axis drives isoproterenol-induced inflammatory heart remodeling. USP38 inhibits type I interferon signaling by editing TBK1 ubiquitination through the NLRP4 signalosome. These findings position K33 deubiquitination as a critical regulator of innate immune and inflammatory responses.
K33-linked deubiquitination in glioblastoma
OTUD4 promotes glioblastoma progression by deubiquitinating CDK1 and activating MAPK signaling. This links K33 deubiquitination to cell cycle control and oncogenic kinase pathways in brain tumors.
From protein K33-linked deubiquitination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ZRANB1-mediated K33 deubiquitination of CTSB promote ferroptosis? | ZRANB1 knockout HCC cells + CTSB K33 mutant knock-in |
| Does YOD1 K33 deubiquitination of NLRP3 protect against sepsis? | YOD1 knockout macrophages + NLRP3 K33 point mutant |
| Does OTUD1 deubiquitinate CARD9 in heart remodeling? | OTUD1 knockout cardiomyocytes + CARD9 K33 mutant |
| Does OTUD4 deubiquitinate CDK1 in glioblastoma? | OTUD4 knockout glioblastoma cells + CDK1 K33 mutant |
| Does TRABID stabilize HECTD1 via K33 deubiquitination? | TRABID knockout cells + HECTD1 K33 mutant |
| Does USP38 edit TBK1 ubiquitination? | USP38 knockout immune cells + TBK1 K33 mutant |
How to Study the protein K33-linked deubiquitination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| K33-linkage-specific immunoprecipitation | Presence of K33-linked ubiquitin chains on substrates | Confirming DUB substrate specificity |
| Mass spectrometry | Ubiquitin chain linkage types and modification sites | Mapping K33 deubiquitination sites |
| CRISPR knockout | Loss-of-function effects of DUBs | Testing causal roles in disease models |
| CRISPR point mutation | Effect of specific K33 residues on substrate function | Dissecting linkage-specific functions |
| CRISPR knock-in | Tagged or mutant protein expression at endogenous loci | Tracking substrate localization and interactions |
| Overexpression | Gain-of-function effects of DUBs or substrates | Rescuing knockout phenotypes |
| Functional assays | Ferroptosis, DIC, heart remodeling, tumor growth, interferon signaling | Linking K33 deubiquitination to disease |
Ubiquitin chain-specific antibodies and immunoprecipitation
K33-linked ubiquitin chains can be detected using linkage-specific antibodies in immunoprecipitation and western blot assays. This method allows researchers to confirm that a substrate carries K33-linked chains and that a DUB removes them.
Mass spectrometry-based ubiquitin chain analysis
Mass spectrometry can identify ubiquitin chain linkages and map deubiquitination sites on substrates such as CTSB, NLRP3, CARD9, CDK1, and HECTD1. This approach provides unbiased evidence for K33-specific cleavage.
CRISPR-based genetic models
CRISPR knockout, point mutation, knock-in, and overexpression models are used to test the causal role of DUBs and substrate K33 residues. These models help distinguish K33-specific effects from other ubiquitin linkages.
Functional assays for downstream phenotypes
Ferroptosis, DIC, heart remodeling, glioblastoma progression, and interferon signaling can be measured using cell viability, coagulation, echocardiography, tumor growth, and reporter assays. These functional readouts link K33 deubiquitination to disease phenotypes.
How CRISPR Can Be Used to Study GO:1990168 protein K33-linked deubiquitination
Knockout
CRISPR knockout of DUBs such as ZRANB1, YOD1, OTUD1, OTUD4, TRABID, and USP38 can reveal their requirement for K33-linked deubiquitination and downstream phenotypes. For example, ZRANB1 knockout reduces CTSB deubiquitination and ferroptosis in HCC cells.
Point Mutation
Point mutation of the K33 residue in ubiquitin or in the substrate can prevent K33-linked chain formation and test specificity. This approach helps distinguish K33-linked deubiquitination from other linkage types.
Knock-in
Knock-in of tagged or mutant DUBs and substrates allows tracking of endogenous proteins and their interactions. For instance, knock-in of a K33 mutant NLRP3 can test its role in sepsis-induced DIC.
Overexpression
Overexpression of DUBs or substrates can rescue knockout phenotypes or drive gain-of-function effects. For example, overexpression of OTUD4 promotes glioblastoma progression via CDK1 deubiquitination.
How EDITGENE Supports protein K33-linked deubiquitination Research
Researchers studying protein K33-linked deubiquitination-related genes often need to determine whether a candidate gene is causally involved in substrate stabilization, signaling, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR cell model and screening services to accelerate these investigations.
Contact EDITGENE today to design your custom CRISPR model for protein K33-linked deubiquitination research.
Frequently Asked Questions About protein K33-linked deubiquitination
What is protein K33-linked deubiquitination?
It is the removal of K33-linked polyubiquitin chains from a protein by deubiquitinating enzymes, as defined by GO:1990168.
What genes are involved in protein K33-linked deubiquitination?
Key genes include ZRANB1, YOD1, OTUD1, OTUD4, TRABID, and USP38, which encode DUBs that cleave K33-linked chains.
Which diseases are linked to K33-linked deubiquitination?
It is linked to hepatocellular carcinoma, sepsis-induced DIC, inflammatory heart remodeling, glioblastoma, and autophagy-related diseases.
How is K33-linked deubiquitination studied?
Researchers use K33-linkage-specific antibodies, mass spectrometry, and CRISPR knockout, point mutation, knock-in, and overexpression models.
What is the role of ZRANB1 in K33-linked deubiquitination?
ZRANB1 removes K33-linked chains from CTSB to promote ferroptosis in HBV-related hepatocellular carcinoma.
How does YOD1 protect against sepsis?
YOD1 deubiquitinates NLRP3 via K33 linkages, protecting against MRSA sepsis-induced DIC.
What is the function of OTUD1 in heart remodeling?
OTUD1 deubiquitinates CARD9 and drives isoproterenol-induced inflammatory heart remodeling.
How does OTUD4 contribute to glioblastoma?
OTUD4 deubiquitinates CDK1 and activates MAPK signaling, promoting glioblastoma progression.
What is the role of TRABID in ubiquitin signaling?
TRABID stabilizes the K29/K48-specific E3 ligase HECTD1 via K33-linked deubiquitination.
How does USP38 regulate interferon signaling?
USP38 inhibits type I interferon signaling by editing TBK1 ubiquitination through the NLRP4 signalosome.
Conclusion
GO:1990168 protein K33-linked deubiquitination is a specialized and reversible process that controls the fate and function of key signaling proteins in inflammation, cancer, and cell death. The growing list of K33-specific DUBs and substrates, including ZRANB1, YOD1, OTUD1, OTUD4, TRABID, and USP38, highlights its broad biological importance. CRISPR-based models are essential to establish causality and to explore therapeutic targeting of this pathway. EDITGENE offers comprehensive services to support these efforts.
References
- 1. Chen W et al.. 2025. MINPP1 promotes ferroptosis in HBV-related hepatocellular carcinoma by regulating CTSB K33-linked deubiquitination via ZRANB1.. Biol Direct 20(1):100 PMID: 41035046
- 2. Liu C et al.. 2024. YOD1 protects against MRSA sepsis-induced DIC through Lys33-linked deubiquitination of NLRP3.. Cell Death Dis 15(5):360 PMID: 38789414
- 3. Qian J et al.. 2024. Macrophage OTUD1-CARD9 axis drives isoproterenol-induced inflammatory heart remodelling.. Clin Transl Med 14(8):e1790 PMID: 39118286
- 4. Ci M et al.. 2024. OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway.. Cell Death Dis 15(3):179 PMID: 38429268
- 5. Harris LD et al.. 2021. The deubiquitinase TRABID stabilizes the K29/K48-specific E3 ubiquitin ligase HECTD1.. J Biol Chem 296:100246 PMID: 33853758
- 6. Wang P et al.. 2018. An OTU deubiquitinating enzyme in Eimeria tenella interacts with Eimeria tenella virus RDRP.. Parasit Vectors 11(1):74 PMID: 29386062
- 7. Lin M et al.. 2016. USP38 Inhibits Type I Interferon Signaling by Editing TBK1 Ubiquitination through NLRP4 Signalosome.. Mol Cell 64(2):267-281 PMID: 27692986
- 8. Feng X et al.. 2019. Ubiquitination of UVRAG by SMURF1 promotes autophagosome maturation and inhibits hepatocellular carcinoma growth.. Autophagy 15(7):1130-1149 PMID: 30686098
